Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11643674 | 0.82 | PPARA (0.70) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Dulofibrate SCHEMBL2110601 | 0.81 | PPARA (0.68) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL2121452 | 0.81 | PPARA (0.68) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL23903398 | 0.79 | PPARA (0.66) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibric Acid SCHEMBL2227936 | 0.77 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL9372364 | 0.77 | PPARA (0.72) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibric Acid SCHEMBL102826 | 0.77 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL135713 | 0.77 | PPARA (0.72) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL10867374 | 0.77 | PPARA (0.72) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL2356 | 0.77 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| WO-2024187239-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | claimed |
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| EP-4262813-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | Topelia Aust Limited (ACN 652 771 670) (AU) | 2023-10-25 | — | — | EP | claimed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | claimed |
| WO-2022126207-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-06-23 | — | — | WO | claimed |
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-20200390858-A1 | Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases | NGM BIOPHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | claimed |
| WO-2009076352-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-18 | — | — | WO | claimed |
| WO-2009073779-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2009073777-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2009020579-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2009020580-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2009005729-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2008153793-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008137139-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | PPARA 915/4885CYP1A2 3080/4885CYP3A4 828/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | PPARA 1110/4885CYP1A2 1173/4885CYP3A4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.